Ardelyx Inc.
34175 Ardenwood Boulevard
Suite 100
Fremont
California
94555
United States
Tel: 510-745-1700
Website: http://www.ardelyx.com/
223 articles about Ardelyx Inc.
-
Ardelyx Stock Trading Halted Today; FDA Advisory Committee to Discuss XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
11/16/2022
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that Nasdaq has halted trading of the Company's common stock.
-
The FDA raised doubts about the future of Ardelyx's experimental chronic kidney disease drug tenapanor in briefing documents released ahead of a Wednesday advisory committee meeting.
-
National Kidney Foundation and Ardelyx, Inc. Survey Finds Dialysis Patients Struggle to Maintain Serum Phosphorus Levels
11/4/2022
Ardelyx, Inc. in partnership with the National Kidney Foundation, announced results from a survey of patients with chronic kidney disease on dialysis conducted to better understand patients' experience managing serum phosphorus levels.
-
Ardelyx Reports Third Quarter 2022 Financial Results and Recent Business Highlights
11/3/2022
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today reported business updates and financial results for the third quarter ended September 30, 2022.
-
Ardelyx Presents New Data Analyses at Kidney Week 2022, Further Supporting the Clinical Relevance of XPHOZAH® (tenapanor), an Investigational, Phosphate Absorption Inhibitor to Control Serum Phosphorus in Adult Patients with CKD on Dialysis
11/3/2022
Ardelyx, Inc. announced that new analyses of data from its three Phase 3 trials supporting the clinical utility of XPHOZAH will be presented at the American Society of Nephrology Kidney Week 2022, taking place in Orlando, Florida from November 3-6, 2022.
-
Ardelyx, Inc. Reports Employment Inducement Grants - November 02, 2022
11/2/2022
Ardelyx, Inc. announced that on October 26, 2022, the compensation committee of the company's board of directors granted three new non-executive employees options to purchase an aggregate of 127,907 shares of the company's common stock, and an aggregate of 31,875 Restricted Stock Units.
-
On Nov. 16, the FDA's Cardiovascular and Renal Drug Advisory Committee will meet to discuss the relative merits of Ardelyx’s tenapanor in chronic kidney disease.
-
Ardelyx Collaboration Partner, Kyowa Kirin, Announces Submission of New Drug Application for Tenapanor for Hyperphosphatemia in Japan
10/31/2022
Ardelyx, Inc. today announced that its collaboration partner in Japan, Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin), has submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare (MHLW) for tenapanor for the improvement of hyperphosphatemia in adult patients with chronic kidney disease (CKD) on dialysis.
-
Ardelyx to Report Third Quarter 2022 Financial Results on November 3, 2022
10/27/2022
Ardelyx, Inc. today announced that it will hold a conference call on Thursday, November 3, 2022, at 4:30 p.m. Eastern Time to review third quarter 2022 financial results and provide a business overview.
-
Ardelyx to Present Poster Presentations on IBSRELA® (tenapanor) for Adult Patients with IBS-C at the American College of Gastroenterology 2022 Annual Scientific Meeting
10/24/2022
Ardelyx, Inc. (Nasdaq: ARDX) today announced that post-hoc analyses from its Phase 3 T3MPO trials will be presented in two posters at the 2022 American College of Gastroenterology Annual Scientific Meeting (ACG 2022) taking place in Charlotte, North Carolina from October 21-26, 2022 and virtually.
-
Ardelyx Announces Poster Presentations on XPHOZAH® (tenapanor) at ASN's Kidney Week 2022
10/20/2022
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced three posters will be presented at the American Society of Nephrology (ASN) Kidney Week 2022 to be held November 3-6, 2022, in Orlando, Florida.
-
Ardelyx, Inc. Reports Employment Inducement Grants - September 30, 2022
9/30/2022
Ardelyx, Inc. announced that on September 26, 2022, the compensation committee of the company's board of directors granted four new non-executive employees options to purchase an aggregate of 56,250 shares of the company's common stock, and an aggregate of 26,000 Restricted Stock Units.
-
Ardelyx to Participate in Upcoming September 2022 Investor Conferences
9/6/2022
Ardelyx, Inc., a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, announced its participation in the following upcoming investor conferences:
-
Ardelyx Reports Second Quarter 2022 Financial Results and Recent Business Highlights
8/4/2022
Ardelyx, Inc. (Nasdaq: ARDX), today reported business updates and financial results for the second quarter ended June 30, 2022.
-
Ardelyx to Present at the 2022 Wedbush PacGrow Healthcare Conference
8/2/2022
Ardelyx, Inc. today announced that Mike Raab , president and chief executive officer of Ardelyx, will participate in a virtual fireside chat at the 2022 Wedbush PacGrow Healthcare Conference. The fireside chat will take place on Tuesday, August 9, 2022, at 4:40 p.m. ET.
-
Ardelyx to Report Second Quarter 2022 Financial Results on August 4, 2022
7/28/2022
Ardelyx, Inc. today announced that it will hold a conference call on Thursday, August 4, 2022, at 4:30 p.m. Eastern Time to review second quarter 2022 financial results and provide a business overview.
-
Ardelyx, Inc. Reports Employment Inducement Grants - July 01, 2022
7/1/2022
Ardelyx, Inc. announced that on June 28, 2022, the compensation committee of the company's board of directors granted six new non-executive employees options to purchase an aggregate of 332,483 shares of the company's common stock, and granted an aggregate of 83,375 Restricted Stock Units to eight new non-executive employees.
-
Ardelyx Announces $20 Million Financing Agreement with HealthCare Royalty Partners
6/30/2022
HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA ® in the United States in exchange for future hyperphosphatemia royalty payments from Ardelyx Japanese collaboration partner.
-
Ardelyx Announces FDA Advisory Committee Meeting to Review XPHOZAH® NDA Tentatively Scheduled for November 16, 2022
6/21/2022
Ardelyx, Inc. (Nasdaq: ARDX), today announced that the U.S. Food and Drug Administration (FDA) has informed the company that a meeting of the Cardiovascular and Renal Drugs Advisory Committee (Advisory Committee) is tentatively scheduled for November 16, 2022.
-
Ardelyx to Present at the Jefferies 2022 Healthcare Conference
6/3/2022
Ardelyx, Inc. will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 10, 2022, at 8:30 a.m. ET in New York City.